Citius Pharmaceuticals Inc vs Sasol Ltd. American Depositary Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Sasol Ltd. American Depositary Shares trades at $14.35 (market cap $9.69B). The key difference: Sasol Ltd. American Depositary Shares is far larger — about 711.5× Citius Pharmaceuticals Inc's market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Sasol Ltd. American Depositary Shares for 0 Days on average.
| CTXR | SSL | |
|---|---|---|
Market Cap | $13.62M | $9.69B |
Volume | 132,438 | 2,297,057 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $15.14 |
52-Week Low | $0.48 | $5.33 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $3.79M | $13.39B |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →